本帖最后由 老马 于 2012-1-13 21:20 编辑 . O, T, v2 x1 l# p S
/ q4 l9 [( ~" L, f6 d
爱必妥和阿瓦斯丁的比较" I( Y; Q) W; q! Z
$ }0 C0 K: L# w9 [http://cancergrace.org/lung/2008/08/30/bms099-os-neg/% q! u; K1 V9 C5 ]" b) ~
; d2 ^ W$ |2 b$ c, `, v
5 v- Y: v( Z1 {$ R! ?6 j+ _
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ O C) r, n4 ]. P' F==================================================
- v, Y9 `* ?3 A4 fOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ h9 B1 H: J$ `7 ^' o
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.; D# t+ V' G6 v- X
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ J# P' O- ]# p# [; \
|